CGIP20076, Zittel, EA2186, 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan
Research Question:
Compares two treatment combinations: gemcitabine hydrochloride and nab-paclitaxel,
or fluorouracil, leucovorin calcium, and liposomal irinotecan in older patients with
pancreatic cancer that has spread to other places in the body (metastatic).
Basic Study Information
Purpose:
This phase II trial compares two treatment combinations: gemcitabine hydrochloride
and nab-paclitaxel, or fluorouracil, leucovorin calcium, and liposomal irinotecan
in older patients with pancreatic cancer that has spread to other places in the body
(metastatic). Drugs used in chemotherapy, such as gemcitabine hydrochloride, nab-paclitaxel,
fluorouracil, leucovorin calcium, and liposomal irinotecan, work in different ways
to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. This study may help doctors find out
which treatment combination is better at prolonging life in older patients with metastatic
pancreatic cancer.
Location: University of Rochester Medical Center
Study Reference #: CGIP20076
Lead Researcher (Principal Investigator)
Lead Researcher:
Jason Zittel
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search